SHPH Share Price Performance
US$3.60
-69.65 (-95.09%)
Price US$3.60
Share PriceUS$3.60
SHPH Community Narratives
There are no narratives available yet.
Recent SHPH News & Updates
No updates
Shuttle Pharmaceuticals Holdings, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -22.69
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 25.0%
Shuttle Pharmaceuticals Holdings, Inc. Competitors
About SHPH
- Founded
- 2012
- Employees
- 9
- CEO
- WebsiteView website
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
In the last week, the market has fallen 1.2%, dragged down most by the Consumer Discretionary. In contrast to the last week, the market is actually up 21% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading